Next Article in Journal
The Coiled Coil and C2 Domains Modulate BCR Localization and BCR-ABL1 Compartmentalization, Transforming Activity and TKI Responsiveness
Previous Article in Journal
Comparative Transcriptomic Profiling in Patients Affected by Duchenne and Becker Muscular Dystrophies: A Focus on ECM Genes Dysregulation
 
 
Review
Peer-Review Record

Gene Therapies in Dermatological Diseases: A Breakthrough in Treatment

Int. J. Mol. Sci. 2025, 26(14), 6592; https://doi.org/10.3390/ijms26146592
by Wiktoria Lisińska 1, Patryk Cegiełka 1, Zuzanna Zalewska 1, Natalia Bien 2, Dorota Sobolewska-Sztychny 2,3, Joanna Narbutt 2 and Aleksandra Lesiak 2,3,*
Reviewer 1:
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2025, 26(14), 6592; https://doi.org/10.3390/ijms26146592
Submission received: 20 May 2025 / Revised: 30 June 2025 / Accepted: 2 July 2025 / Published: 9 July 2025
(This article belongs to the Section Molecular Pathology, Diagnostics, and Therapeutics)

Round 1

Reviewer 1 Report

Comments and Suggestions for Authors

Dear authors,

The manuscript entitled “Gene therapies in dermatological diseases: an advance in treatment” is a review focused on the new therapeutic approaches with gene therapies in skin diseases, presenting the clinical and academic scenario.

The manuscript is relevant and modern, and when reading it, some questions arose. I would like to obtain information from the authors regarding the following:

- How is the stability and purity study of these therapeutic genes conducted?

- What are the main attributes analyzed in the quality control test of these therapeutic genes?

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

Comments and Suggestions for Authors

This review on recent progresses on Gene therapy treatments in dermatological diseases presented different strategies in gene therapy and how they could be applied to various dermatological conditions. A few comments for the authors are listed below:

(1) While the introduction to gene therapy in dermatology in the manuscript is well-organized, a brief overview of traditional treatments and their shortcomings compared to gene therapy could be beneficial for a broader audience.

(2) As the authors introduced many cutting-edge gene therapy strategies that have not been FDA approved yet, like the siRNA-based treatment, more information on any preclinical or in vivo study progress would be helpful.

(3) For Table 2, if the references can be categorized based on different gene therapy treatment types among each disease, it would be easier for the readers to look into references for specific treatment.

Author Response

"Please see the attachment."

Author Response File: Author Response.pdf

Back to TopTop